百奧泰是一家位于中國廣州，基于科學而創新的全球性生物制藥企業。公司致力于開發新一代創新藥和生物類似藥，用于治療腫瘤、自身免疫性疾病、心血管疾病、眼科以及其它危及人類生命或健康的疾病。作為新一代抗體藥物研發的領導者，百奧泰已推動多款候選藥物進入后期臨床試驗，其中格樂立?（阿達木單抗）、普貝希?（貝伐珠單抗）、施瑞立?（托珠單抗）已在中國獲批上市。TOFIDENCETM（托珠單抗），Avzivi?（貝伐珠單抗）已在美國獲批。公司現有20多款在研產品處于不同臨床研究階段，其中腫瘤領域主要聚焦后PD-1時代的腫瘤免疫治療和抗體藥物偶聯體（ADC）靶向藥物開發。百奧泰始終以患者的福祉作為首要核心價值，通過創新研發，為患者提供安全、有效、可負擔的優質藥物，以滿足亟待解決的治療需求。欲了解更多信息，請訪問www.bio-thera.com，或關注我們的推特（@bio_thera_sol）和微信公眾號（百奧泰）。Bio-Thera Solutions, Ltd., a leading innovative, global biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs, as well as biosimilars of existing, branded biologics to treat a range of cancer and autoimmune diseases.As a leader in next generation antibody discovery and engineering, the company has advanced multiple candidates into late-stage development, including three approved products: QLETLI? in China, and TOFIDENCE?/ BAT1806 and Avzivi?/Pobevcy? in the US and China. In addition, the company has more than 20 promising candidates in clinical trials, focusing on immuno-oncology in the post-PD-1 era and targeted therapies such as ADCs. For more information, please visit www.bio-thera.com/en/ or follow us on Twitter(@bio_thera_sol) and WeChat(Bio-Thera).